Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

August 28, 2024
PDF Version

ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for oral presentation and ten abstracts for poster presentation at the upcoming 7th Bradykinin Symposium, to be held from September 5-6, 2024, in Berlin, Germany. Presentation details are as follows:

  • Title: Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat
    Presenter: Jolanta Skarbaliene, Ph.D.
    Format: Oral Presentation, Session II
    Date, time: Thursday, Sept. 5, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)
  • Title: Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoL
    Presenter: Markus Magerl, M.D.
    Format: Oral Presentation, Session VII
    Date, time: Friday, Sept. 6, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis
    Presenter: Marc A. Riedl, M.D., M.S.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Treatment of HAE Attacks with Oral Deucrictibant: RAPIDe-2 Extension Results
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 Results
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis
    Presenter: Marc A. Riedl, M.D., M.S.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Clinical Trials Conformity with AURORA COS: a systematic literature review
    Presenter: Remy Petersen, M.D., Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibant
    Presenter: Nieves Crespo, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: The bradykinin challenge model translates across rat, monkey and human
    Presenter: Juan Bravo, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Deucrictibant inhibits carrageenan-induced edema in bradykinin B2 receptor transgenic rat
    Presenter: Anne Lesage, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: A novel kinin biomarker assay for characterization of bradykinin-mediated disorders
    Presenter: Evangelia Pardali, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disorders
    Presenter: Evangelia Pardali, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

Upon lift of the embargo, the presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of HAE effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both in the prophylactic and on-demand setting. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks in the coming months. For more information, visit https://pharvaris.com/.


Contact Maggie Beller Executive Director, Head of External and Internal Communications maggie.beller@pharvaris.com